Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Tafamidis Soft Gel Capsules
NCT02534740Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tafamidis in transthyretin amyloidosis (ATTR) (5 arms), sponsored by Pfizer. Primary endpoints: Area under the concentration-time Curve at 120 hours and Maximum Observed Plasma Concentration at 120 hours. Started Sep 2015; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT02534740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02534740.